Sareum sees hike in share prices thanks to inhibitor

- Last updated on GMT

Related tags: Cancer

Shares in drug discovery company Sareum have soared by 36 per cent after the firm announced the selection of a preclinical development candidate for its Checkpoint kinase 1 (Chk1) inhibitor programme.

Chk1 is an enzyme that controls a cancer cell's response to DNA damage, either caused by the disease itself or by the treatment; chemotherapy or radiotherapy.

Preclinical studies have shown that when Chk1 is taken in combination with chemotherapeutic drugs, it reduces cancer growth rates compared to treatment with the same dose of chemotherapeutic without the Chk1 inhibitor.

Now the Cambridge-based company are working with the Institute of Cancer Research (ICR) and Cancer Research UK’s commercial arm, and Cancer Research Technology Limited (CRT).

Shares have been hiked from 0.46 pence (36 per cent) to 1.71 pence.

Sareum chief executive, Tim Mitchell, said: “The selection of a preclinical development candidate is a major milestone for the collaboration that will significantly enhance the licensing package.

“Our research indicates that the selectivity and oral dosing properties of this candidate give it a competitive advantage.”

Related news

Related products

show more

A Better Approach, for Better Pain Trials

A Better Approach, for Better Pain Trials

Signant Health | 27-Sep-2021 | Technical / White Paper

Pain studies face unique challenges. For one, pain severity can only be truly assessed by the patients themselves. The controlled substances that are often...

Q&A: Effective Drug Product Process Development

Q&A: Effective Drug Product Process Development

Catalent Pharma Solutions | 14-Jan-2021 | Insight Guide

In this Q&A, a Catalent Biologics expert shares his expertise with drug product process development challenges, risks and how to mitigate them, the...

Related suppliers

Follow us

Products

View more

Webinars